STAT3 and cancer: In vitro evidence supporting that Ruxolitinib induced decreases in cytokine levels and disruption of STAT3 activation via upstream signaling suggests a role for Ruxolitinib in cancer cases characterized by elevated IL-6 levels [132,133,134,135,136].